United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - colestyramine anhydrous - powder for oral suspension - 4gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - colestyramine anhydrous - powder for oral suspension - 4gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - colestyramine anhydrous - powder for oral suspension - 4gram

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 1025.2 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 512.6 mg - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية الاموي - al-omawai drug store - colestyramine 4 gm/1 sac - 4 gm/1 sac

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - colestyramine -

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cheplapharm arzneimittel gmbh - colestyramine 4 g - powder for oral suspension - 4 g - colestyramine 4 g - colestyramine

Malta - English - Malta Medicines Authority

laboratorios rubio s.a industria, 29, pol.ind. comte de sert, 08755 castellbisbal, barcelona, spain - colestyramine - powder for oral suspension - colestyramine 4 g - lipid modifying agents

Malta - English - Malta Medicines Authority

central procurement & supplies unit - colestyramine - powder for oral suspension - colestyramine 4 g - lipid modifying agents